Imvax

Imvax, Inc. is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies for solid tumors. Their most advanced program, IGV-001, is in a Phase 2b clinical trial for newly diagnosed glioblastoma. The company utilizes its proprietary Goldspire® immuno-oncology platform to induce a broad and durable immune response against tumors.

Buy Funded Startups lists

Funding Round:

Funding Amount: $29M

Date: 29-Jan-2025

Investors: existing investors

Markets: Biotechnology, Immunotherapy, Pharmaceutical, Therapeutics, Oncology

HQ: Philadelphia, Pennsylvania, United States

Founded: 2015

Website: https://www.imvax.com/

LinkedIn: https://www.linkedin.com/company/imvax-inc

Twitter: https://twitter.com/imvax_inc

Instagram: